• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Recognized Consensus Standards

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

New Search Back To Search Results
Part B: Supplementary Information Sheet (SIS)
FR Recognition List Number 051 Date of Recognition 01/14/2019 
FR Recognition Number 2-258
Standard
ISO 10993-1 Fifth edition 2018-08
Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process
Scope/Abstract
This document specifies:

- the general principles governing the biological evaluation of medical devices within a risk management process;

- the general categorization of medical devices based on the nature and duration of their contact with the body;

- the evaluation of existing relevant data from all sources;

- the identification of gaps in the available data set on the basis of a risk analysis;

- the identification of additional data sets necessary to analyse the biological safety of the medical device;

- the assessment of the biological safety of the medical device.

This document applies to evaluation of materials and medical devices that are expected to have direct or indirect contact with:

- the patient's body during intended use;

- the user's body, if the medical device is intended for protection (e.g., surgical gloves, masks and others).

This document is applicable to biological evaluation of all types of medical devices including active, non-active, implantable and non-implantable medical devices.

This document also gives guidelines for the assessment of biological hazards arising from:

- risks, such as changes to the medical device over time, as a part of the overall biological safety assessment;

- breakage of a medical device or medical device component which exposes body tissue to new or novel materials.

Other parts of ISO 10993 cover specific aspects of biological assessments and related tests. Device-specific or product standards address mechanical testing.

This document excludes hazards related to bacteria, moulds, yeasts, viruses, transmissible spongiform encephalopathy (TSE) agents and other pathogens.

Extent of Recognition
Partial recognition. The following part(s) of the standard is (are) not recognized
Table A.1 in Annex A.
Rationale for Recognition
This standard is relevant to medical devices and is recognized on its scientific and technical merit and/or because it supports existing regulatory policies.
This standard is recognized in part because:
Table A.1 in Annex A is in conflict with an existing published final guidance, see Attachment A, Table A1 of the guidance listed below.
Transition Period
FDA recognition of ISO 10993-1 Fourth edition 2009-10-15 [Rec# 2-220] will be superseded by recognition of ISO 10993-1 Fifth edition 2018-08 [Rec# 2-258]. FDA will accept declarations of conformity, in support of premarket submissions, to [Rec# 2-220] until December 26 , 2020. After this transition period, declarations of conformity to [Rec# 2-220] will not be accepted.
Public Law, CFR Citation(s) and Procode(s)
21 CFR 58 Good Laboratory Practice for Nonclinical Laboratory Studies
Relevant FDA Guidance and/or Supportive Publications
Guidance for Industry and Food and Drug Administration Staff: Use of International Standard ISO 10993-1, "Biological evaluation of medical devices--Part 1: Evaluation and testing within a risk management process", Issued June 2016.
FDA Technical Contacts
 Jennifer Goode
  FDA/OMPT/CDRH/ODE/DCD/PIDB/
  301-796-6374
  jennifer.goode@fda.hhs.gov
 Michael Bailey
  FDA/OMPT/CDRH/ODE/DRGUD/OGDB/
  301-796-6530
  michael.bailey@fda.hhs.gov
Standards Development Organization
ISO International Organization for Standardization https://www.iso.org/
FDA Specialty Task Group (STG)
Biocompatibility
-
-